United States securities and exchange commission logo





                              May 9, 2022

       Robert Wessman
       Executive Chairman
       Alvotech Lux Holdings S.A.S.
       9, Rue de Bitbourg
       L-1273 Luxembourg
       Grand Duchy of Luxembourg

                                                        Re: Alvotech Lux
Holdings S.A.S.
                                                            Amendment No. 5 to
Registration Statement on Form F-4
                                                            Filed May 2, 2022
                                                            File No. 333-261773

       Dear Mr. Wessman:

             We have reviewed your amended registration statement and have the
following
       comments. In some of our comments, we may ask you to provide us with
information so we
       may better understand your disclosure.

              Please respond to this letter by amending your registration
statement and providing the
       requested information. If you do not believe our comments apply to your
facts and
       circumstances or do not believe an amendment is appropriate, please tell
us why in your
       response.

              After reviewing any amendment to your registration statement and
the information you
       provide in response to these comments, we may have additional comments.
Unless we note
       otherwise, our references to prior comments are to comments in our April
28, 2022 letter.

       Amendment No. 5 to Registration Statement on Form F-4

       Questions and Answers About the Business Combination
       Q: Will OACB, TopCo and Alvotech be obtaining new financing in
connection with the
       Business Combination?, page 9

   1.                                                   We note your response
to prior comment 1. Please also disclose here that the new
                                                        financing is needed for
additional liquidity in the event of high redemptions, consistent
                                                        with your disclosure on
page 160.
 Robert Wessman
Alvotech Lux Holdings S.A.S.
May 9, 2022
Page 2
Summary of the Proxy Statement/Prospectus
The Business Combination
Conditions to Closing, page 30

2.    We note your revised disclosure here in response to our prior comment 1
to further clarify
      amendments to the minimum cash condition and aggregate transaction
proceeds that were
      made in the BCA Amendment. We also note your revised disclosure on page
189 where
      you state that "[t]he $90,000,000 refers to the Loan Advances with
Alvogen and Aztiq for
      an amount of $50.0 million and the Alvogen Bridge Loan for up to $40.0
million" and
      that "[a]ny debt financing funded to Alvotech or available to be funded
in addition to
      these aforementioned facilities, including the Sculptor facility and
potential other debt
      facilities, whether from shareholders or third parties, will count
towards the $250,000,000
      Minimum Cash Condition." Please revise your disclosure here to provide
similar
      clarification regarding to what the $90.0 million refers and which of
your debt facilities
      may count towards the minimum cash condition.
        You may contact Franklin Wyman at 202-551-3660 or Vanessa Robertson at
202-551-
3649 if you have questions regarding comments on the financial statements and
related
matters. Please contact Jessica Ansart at 202-551-4511 or Jeffrey Gabor at
202-551-2544 with
any other questions.



                                                           Sincerely,
FirstName LastNameRobert Wessman
                                                           Division of
Corporation Finance
Comapany NameAlvotech Lux Holdings S.A.S.
                                                           Office of Life
Sciences
May 9, 2022 Page 2
cc:       Nicolas Dumont
FirstName LastName